METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer
We elucidate that an underappreciated function of truncated APC in CRC is its ability to drive an immunosuppressive program that boosts tumor progression. Our work could provide a new perspective for the clinical application of immunotherapy in patients with CRC resistant to ICB therapy.
Authors
- Rui Bai (ORCID: https://orcid.org/0000-0002-3025-9975)
- Jianghua Wu (ORCID: https://orcid.org/0000-0001-7351-8933)
- Zetao Chen (ORCID: https://orcid.org/0000-0003-1982-8847)
- Hao Chen (ORCID: https://orcid.org/0000-0003-0018-480X)
- Hui Wang (ORCID: https://orcid.org/0000-0003-2791-8981)
- Liang Zhao (ORCID: https://orcid.org/0000-0002-1429-0884)
- Ling Wu
- Yujie Zhang (ORCID: https://orcid.org/0000-0002-5524-2790)
Institutions
- The First People's Hospital of Shunde (CN)
- Zhujiang Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-009865
- Citations
- 9
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.10
Funders
- Natural Science Foundation of Guangzhou City
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Guangdong Province